6.06
price up icon8.99%   0.50
after-market Handel nachbörslich: 6.06
loading
Schlusskurs vom Vortag:
$5.56
Offen:
$5.45
24-Stunden-Volumen:
456.94K
Relative Volume:
0.74
Marktkapitalisierung:
$295.11M
Einnahmen:
$15.84M
Nettoeinkommen (Verlust:
$-308.48M
KGV:
-1.5381
EPS:
-3.94
Netto-Cashflow:
$-153.08M
1W Leistung:
-5.61%
1M Leistung:
+7.26%
6M Leistung:
+29.21%
1J Leistung:
-0.90%
1-Tages-Spanne:
Value
$5.35
$6.065
1-Wochen-Bereich:
Value
$5.35
$6.48
52-Wochen-Spanne:
Value
$3.73
$11.35

Uniqure N V Stock (QURE) Company Profile

Name
Firmenname
Uniqure N V
Name
Telefon
1-339-970-7000
Name
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Name
Mitarbeiter
480
Name
Twitter
@uniQure_NV
Name
Nächster Verdiensttermin
2024-07-30
Name
Neueste SEC-Einreichungen
Name
QURE's Discussions on Twitter

Uniqure N V Stock (QURE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2022-03-17 Hochstufung UBS Neutral → Buy
2021-06-15 Eingeleitet BTIG Research Buy
2021-05-21 Eingeleitet UBS Neutral
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-04-01 Hochstufung Mizuho Neutral → Buy
2021-01-07 Hochstufung Guggenheim Neutral → Buy
2020-11-24 Eingeleitet H.C. Wainwright Buy
2020-11-11 Eingeleitet Berenberg Buy
2020-11-09 Eingeleitet Jefferies Buy
2020-11-04 Eingeleitet Cantor Fitzgerald Overweight
2020-10-23 Eingeleitet RBC Capital Mkts Outperform
2020-08-25 Eingeleitet Raymond James Strong Buy
2020-07-31 Hochstufung Robert W. Baird Neutral → Outperform
2020-06-25 Herabstufung Mizuho Buy → Neutral
2020-06-25 Herabstufung Robert W. Baird Outperform → Neutral
2020-06-25 Herabstufung Wells Fargo Overweight → Equal Weight
2019-12-03 Eingeleitet Cowen Outperform
2019-12-03 Eingeleitet Goldman Buy
2019-11-05 Eingeleitet Credit Suisse Outperform
2019-10-11 Eingeleitet Stifel Buy
2019-09-25 Eingeleitet Bernstein Outperform
2019-09-12 Eingeleitet Mizuho Buy
2019-07-30 Herabstufung Guggenheim Buy → Neutral
2019-07-08 Bestätigt Cantor Fitzgerald Overweight
2019-04-12 Eingeleitet Piper Jaffray Overweight
2019-03-29 Eingeleitet Robert W. Baird Outperform
Alle ansehen

Uniqure N V Aktie (QURE) Neueste Nachrichten

pulisher
09:52 AM

Uniqure NV earnings beat by $0.11, revenue fell short of estimates - Investing.com

09:52 AM
pulisher
08:44 AM

uniQure NV Q3 2024 Earnings: EPS Loss of $0.91 Beats Estimates, Revenue of $2.3 Million Misses Expectations - GuruFocus.com

08:44 AM
pulisher
08:37 AM

UniQure: Q3 Earnings Snapshot - San Antonio Express-News

08:37 AM
pulisher
08:30 AM

uniQure reports Q3 EPS (91c), consensus ($1.01) - TipRanks

08:30 AM
pulisher
08:30 AM

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

08:30 AM
pulisher
07:09 AM

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire

07:09 AM
pulisher
07:05 AM

UniQure N.V. Reports Earnings Results for the Third Quarter Ended September 30, 2024 - Marketscreener.com

07:05 AM
pulisher
Nov 03, 2024

abrdn plc Buys 1,528,581 Shares of uniQure (NASDAQ:QURE) - MarketBeat

Nov 03, 2024
pulisher
Nov 02, 2024

Assenagon Asset Management S.A. Has $1.34 Million Stake in uniQure (NASDAQ:QURE) - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Multiple Insiders Sold uniQure Shares Presenting Weak Signs For Investors - Simply Wall St

Nov 01, 2024
pulisher
Oct 29, 2024

UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance

Oct 29, 2024
pulisher
Oct 28, 2024

(QURE) Investment Analysis - Stock Traders Daily

Oct 28, 2024
pulisher
Oct 26, 2024

uniQure (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 26, 2024
pulisher
Oct 25, 2024

Pfizer Loses Hemophilia Gene Therapy Patent Row To UniQure - Law360

Oct 25, 2024
pulisher
Oct 20, 2024

uniQure’s Yellow Flags: Early-Stage Gene Therapies Amid Restructuring - Seeking Alpha

Oct 20, 2024
pulisher
Oct 18, 2024

State Street Corp's Strategic Reduction in uniQure NV Holdings - GuruFocus.com

Oct 18, 2024
pulisher
Oct 18, 2024

How To Trade (QURE) - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 17, 2024

uniQure (NASDAQ:QURE) Upgraded at StockNews.com - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

uniQure (NASDAQ:QURE) Upgraded by StockNews.com to “Sell” - Defense World

Oct 17, 2024
pulisher
Oct 15, 2024

uniQure N.V. (QURE) requires closer examination - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

uniQure Initiates Trial for Promising ALS Gene Therapy - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

uniQure announces dosing of first patient in Phase I/II trial of AMT-162 - TipRanks

Oct 15, 2024
pulisher
Oct 15, 2024

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewswire

Oct 15, 2024
pulisher
Oct 15, 2024

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - StockTitan

Oct 15, 2024
pulisher
Oct 14, 2024

Raymond James gives an Outperform recommendation for uniQure N.V. (QURE) - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Ratios Uncovered: Breaking Down uniQure N.V. (QURE)’s Trailing Twelve Months Metrics - The Dwinnex

Oct 14, 2024
pulisher
Oct 13, 2024

Marshall Wace LLP Invests $175,000 in uniQure (NASDAQ:QURE) - Defense World

Oct 13, 2024
pulisher
Oct 10, 2024

uniQure shares coverage resumed on robust clinical portfolio - Investing.com

Oct 10, 2024
pulisher
Oct 10, 2024

Raymond James Reiterates Outperform Rating for uniQure (NASDAQ:QURE) - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

uniQure shares coverage resumed on robust clinical portfolio By Investing.com - Investing.com UK

Oct 10, 2024
pulisher
Oct 10, 2024

A company insider recently sold 1,447 shares of uniQure N.V. [QURE]. Should You Sale? - Knox Daily

Oct 10, 2024
pulisher
Oct 09, 2024

An analyst sees good growth prospects for uniQure N.V. (QURE) - SETE News

Oct 09, 2024
pulisher
Oct 09, 2024

Market Recap: uniQure N.V. (QURE)’s Positive Momentum, Closing at 5.92 - The Dwinnex

Oct 09, 2024
pulisher
Oct 08, 2024

The uniQure N.V. (QURE) had a good session last reading, didn’t it? - US Post News

Oct 08, 2024
pulisher
Oct 07, 2024

uniQure N.V.’s Mixed Bag: Up 9.71% in 6 Months, Up 2.17% in 30 Days - The InvestChronicle

Oct 07, 2024
pulisher
Oct 02, 2024

uniQure (NASDAQ:QURE shareholders incur further losses as stock declines 10% this week, taking five-year losses to 89% - Simply Wall St

Oct 02, 2024
pulisher
Oct 01, 2024

Technical analysis of uniQure N.V. (QURE) stock chart patterns - US Post News

Oct 01, 2024
pulisher
Oct 01, 2024

uniQure (NASDAQ:QURE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Insider Sale Alert: uniQure N.V. [QURE] – Is it Time to sell? - Knox Daily

Sep 30, 2024
pulisher
Sep 29, 2024

Doheny Asset Management CA Acquires Shares of 27,080 uniQure (NASDAQ:QURE) - Defense World

Sep 29, 2024
pulisher
Sep 28, 2024

uniQure (NASDAQ:QURE) Shares Cross Below Two Hundred Day Moving Average of $5.63 - MarketBeat

Sep 28, 2024
pulisher
Sep 24, 2024

When (QURE) Moves Investors should Listen - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 23, 2024

FDA grants Orphan Drug status to uniQure's Fabry therapy By Investing.com - Investing.com Canada

Sep 23, 2024
pulisher
Sep 23, 2024

UniQure rises on orphan drug status for genetic disorder gene therapy - XM

Sep 23, 2024
pulisher
Sep 23, 2024

uniQure Gains FDA Orphan Drug Status for Fabry Disease Therapy - TipRanks

Sep 23, 2024
pulisher
Sep 23, 2024

FDA grants Orphan Drug status to uniQure's Fabry therapy - Investing.com India

Sep 23, 2024
pulisher
Sep 23, 2024

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease - GlobeNewswire

Sep 23, 2024
pulisher
Sep 20, 2024

uniQure's (QURE) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat

Sep 20, 2024
pulisher
Sep 20, 2024

uniQure (NASDAQ:QURE) Given Overweight Rating at Cantor Fitzgerald - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

How did uniQure N.V. (QURE) fare last session? - US Post News

Sep 19, 2024
pulisher
Sep 14, 2024

Acadian Asset Management LLC Reduces Holdings in uniQure (NASDAQ:QURE) - MarketBeat

Sep 14, 2024

Finanzdaten der Uniqure N V-Aktie (QURE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Uniqure N V-Aktie (QURE) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
CALOZ PIERRE
Chief Operating Officer
Jun 17 '24
Sale
4.81
2,936
14,122
115,707
KLEMT CHRISTIAN
Chief Financial Officer
Jun 17 '24
Sale
4.80
1,611
7,733
164,837
POST LEONARD E
Director
Jun 13 '24
Sale
5.14
2,222
11,421
15,999
Potts Jeannette
Chief Legal Officer
Jun 13 '24
Sale
4.98
4,781
23,809
91,819
Springhorn Jeremy P.
Director
Jun 13 '24
Sale
5.12
2,231
11,423
23,756
Meek David D.
Director
Jun 13 '24
Sale
5.12
2,229
11,412
20,252
Balachandran Madhavan
Director
Jun 13 '24
Sale
5.12
2,231
11,423
23,759
Soteropoulos Paula
Director
Jun 13 '24
Sale
5.14
2,220
11,411
20,203
Gut Robert
Director
Jun 13 '24
Sale
5.12
3,504
17,940
44,165
Kaye Jack
Director
Jun 13 '24
Sale
5.16
2,218
11,445
6,501
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):